JNJ-2113 maintained skin clearance in adults with moderate-to-severe plaque psoriasis over one year in the FRONTIER 2 study, showing sustained efficacy and safety.
Johnson & Johnson's JNJ-2113, an investigational oral peptide targeting the IL-23 receptor, maintained skin clearance in adults with moderate-to-severe plaque psoriasis over one year, according to data from the FRONTIER 2 long-term extension study. The findings demonstrated sustained efficacy from Week 16 to Week 52 and consistent safety results compared to previous data. JNJ-2113 may have potential for treating additional IL-23-mediated diseases.
March 09, 2024
3 Articles